Nevakar Inc.
  • Home
  • comp001
    • comp001b
  • comp002
  • Nevakar
  • NevakarInjectables
  • Vyluma
Select Page

Industry Focus: A Look at Nevakar

by @dministrator | Mar 1, 2021 | NevakarInjectables | 0 comments

By JASON J. NICHOLS, OD, MPH, PHD

View the article | CLICK HERE

Dr. Puri, please tell us about your company in terms of its history and direction…

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
  • Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
  • Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
  • VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS
  • VYLUMA INC LAUNCHES WITH ROBUST OPHTHALMIC PORTFOLIO, LEADING WITH A PHARMACEUTICAL TREATMENT IN PHASE III FOR MYOPIA

Recent Comments

    Archives

    • March 2022
    • October 2021
    • May 2021
    • March 2021
    • January 2021
    • November 2020
    • October 2020
    • August 2020
    • May 2020
    • November 2019
    • October 2019
    • September 2019
    • June 2019
    • August 2018
    • November 2017
    • June 2017
    • July 2016
    • June 2015

    Categories

    • NevakarInjectables
    • Vyluma

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Facebook
    • Twitter
    • Google
    • Instagram
    • RSS

    Designed by Elegant Themes | Powered by WordPress